The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene homozygous deletion has also been shown to be associated with dismal outcomes for IDH-mutant gliomas lacking 1p/19q codeletion, as well as for anaplastic ODs. Here, CDKN2A is linked to glioma.